Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

NCT04360941 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT04360941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04360941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 11, 2020
Completion date
July 31, 2027
Enrollment
45 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

er+ breast cancer, her2-positive breast cancer, locally advanced breast cancer, metastatic breast cancer, recurrent breast cancer, triple negative breast cancer